Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study

Abstract

IntroductionCurrently used tools for breast cancer prognostication and prediction may not adequately reflect a young patient’s prognosis or likely treatment benefit because they were not adequately validated in young patients. Since breast cancers diagnosed at a young age are considered prognostically unfavourable, many treatment guidelines recommend adjuvant systemic treatment for all young patients. Patients cured by locoregional treatment alone are, therefore, overtreated. Lack of prognosticators for young breast cancer patients represents an unmet medical need and has led to the initiation of the PAtients with bReAst cancer DIaGnosed preMenopausally (PARADIGM) initiative. Our aim is to reduce overtreatment of women diagnosed with breast cancer aged ≤40 years.Methods and analysisAll young, adjuvant systemic treatment naive breast cancer patients, who had no prior malignancy and were diagnosed between 1989 and 2000, were identified using the population based Netherlands Cancer Registry (n=3525). Archival tumour tissues were retrieved through linkage with the Dutch nationwide pathology registry. Tissue slides will be digitalised and placed on an online image database platform for clinicopathological revision by an international team of breast pathologists. Immunohistochemical subtype will be assessed using tissue microarrays. Tumour RNA will be isolated and subjected to next-generation sequencing. Differences in gene expression found between patients with a favourable and those with a less favourable prognosis will be used to establish a prognostic classifier, using the triple negative patients as proof of principle.Ethics and disseminationObservational data from the Netherlands Cancer Registry and left over archival patient material are used. Therefore, the Dutch law on Research Involving Human Subjects Act (WMO) is not applicable. The PARADIGM study received a ‘non-WMO’ declaration from the Medical Ethics Committee of the Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, waiving individual patient consent. All data and material used are stored in a coded way. Study results will be presented at international (breast cancer) conferences and published in peer-reviewed, open-access journals.

Being fully digital: perspective of a Dutch academic pathology laboratory

“…Digitisation of glass slides has enabled laboratories to avoid shipping glass slides around, which permits laboratories to hold onto the physical glass slides, and instead send out digital copies. Large review research projects can be performed more quickly by having all cases digitised and hosted on a central location, allowing access for pathologists to review cases independently of their location . Pathologists can review cases from the convenience of their home or while being remote at, for example, meetings.…”

“…Large review research projects can be performed more quickly by having all cases digitised and hosted on a central location, allowing access for pathologists to review cases independently of their location. 11 Pathologists can review cases from the convenience of their home or while being remote at, for example, meetings.…”

Digital pathology in the time of corona

“… 1 With the promise to replace the microscope, digital whole slide images (WSIs) could be viewed on computer screens and shared real time among colleagues without having to ship glass slides around. Apart from the most basic use case, which is remote viewing, digital pathology includes use cases such as archiving, 2 research, 3 4 teaching, 5 6 streamlining multidisciplinary meetings, 2 remote diagnosis (eg, frozen sections), 7 remote consultation 8 9 and primary diagnostics 10–14 for which proper validation studies have been performed. 14 15 …”

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences

“…For this, a matched case-control study could be set up using the Netherlands Cancer Registry database coupled with the nationwide digital pathology archive, through which tumour material can be recollected for research purposes, e.g., the PARADIGM initiative. 39…”